Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab

Annals of the Rheumatic Diseases
Chamaida PlasenciaAlejandro Balsa

Abstract

Infliximab (IFX) is a monoclonal antibody against tumour necrosis factor α that is effective for treating spondyloarthritis (SpA). However, after initial success of the drug some patients lose responsiveness or develop infusion reactions, which may be related to the development of antibodies against the drug. To investigate the clinical relevance of antibodies to infliximab (ATI) formation in patients with SpA undergoing IFX treatment over a prolonged period. 94 patients with SpA treated with IFX from 1999 to 2010 were studied. Their clinical characteristics, serum trough IFX levels and ATI status were evaluated for a mean of 6.99 (95% CI:6.28 to 7.7) years. Clinical activity and improvement were measured using the Ankylosing Spondylitis Disease Activity Score (ASDAS): inactive <1.3, moderate ≥1.3 and <2.1, high ≥2.1-≤3.5, and very high >3.5 at three time points (6 months, 12 months and >4 years). ATI were detected in 24 (25.5%) patients. The patients with ATI had higher ASDAS scores than those without ATI (2.55±0.89 vs 1.79±1.04, p=0.038 at 6 months; 1.95±0.67 vs 1.67±0.71, p=0.042 at 1 year; 2.52±0.99 vs 1.53±0.81, p=0.024 at >4 years). Eleven patients (12%) developed infusion-related reactions, and of these, ATI were present...Continue Reading

Citations

Apr 2, 2014·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Gianfranco Pasut
Oct 11, 2013·Expert Opinion on Biological Therapy·Clara De SimoneFrancesca Prestinari
Sep 24, 2015·Expert Review of Gastroenterology & Hepatology·Shomron Ben-HorinYehuda Chowers
Apr 30, 2013·Actas dermo-sifiliográficas·J M Carrascosa
Aug 15, 2014·The Journal of Investigative Dermatology·Denis JullienFrank O Nestle
May 21, 2014·Journal of the European Academy of Dermatology and Venereology : JEADV·J-M CarrascosaJ C Prinz
Aug 19, 2015·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Sarah S ThomasDaniel E Furst
Nov 21, 2014·Rheumatology International·Diana Hernández-FlórezLuis Carreño
Apr 18, 2015·Arthritis Research & Therapy·Ariana MontesAntonio Gonzalez
Apr 22, 2015·Multiple Sclerosis and Related Disorders·Evelyn Walter, Florian Deisenhammer
Jan 15, 2014·Joint, Bone, Spine : Revue Du Rhumatisme·Daniel WendlingUNKNOWN French Society for Rheumatology (SFR)
May 12, 2017·Expert Review of Clinical Pharmacology·Santhi MantravadiWalter K Kraft
Dec 8, 2016·Expert Opinion on Drug Safety·Andrea MatucciAlessandra Vultaggio
Jan 27, 2016·The Journal of International Medical Research·Mohammed HammoudehUppal Sukhbir
Apr 6, 2017·Therapeutic Drug Monitoring·Frédéric MedinaDenis Mulleman
May 10, 2017·Therapeutic Drug Monitoring·Gilles PaintaudDenis Mulleman
May 4, 2017·Therapeutic Drug Monitoring·Karien BloemTheo Rispens
Oct 13, 2016·The Korean Journal of Internal Medicine·Hyemin JeongHoon-Suk Cha
Oct 6, 2018·Dermatologic Therapy·Agnieszka Owczarczyk-SaczonekAdriana Rakowska
Aug 2, 2017·The Open Rheumatology Journal·Jurado TeresaPascual-Salcedo Dora
Apr 3, 2019·Expert Opinion on Drug Safety·Giuseppe MurdacaFrancesco Puppo
Aug 15, 2013·Therapeutic Drug Monitoring·Maarten L ZandvlietTeun van Gelder
Jul 18, 2019·British Journal of Clinical Pharmacology·María José Fobelo LozanoSusana Sánchez Fidalgo
Feb 24, 2015·Pharmacological Reviews·Stefan SiebertIain McInnes
Oct 23, 2019·Expert Review of Clinical Immunology·Andrea MatucciAlessandra Vultaggio
Aug 7, 2013·Clinical Chemistry and Laboratory Medicine : CCLM·Begoña Ruiz-ArgüelloDaniel Nagore

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.